The Fairness to Kids with Cancer Act of 2025 requires that a proportional share of federal cancer research funding be devoted to pediatric cancer research. For FY2026 and each subsequent year, the President must ensure that the share allocated to pediatric cancer research equals a Census-based percentage calculated from population data.
The percentage is defined as the ratio of the number of individuals under 18 residing in the United States at the end of the preceding fiscal year to the total U.S. population, as determined by the Bureau of the Census. The bill does not specify penalties or enforcement mechanisms beyond compelling executive budgeting toward this proportional share.
At a Glance
What It Does
For FY2026 and later, the President must ensure that the percentage of federal cancer research funds obligated for pediatric cancer research equals the Census-derived share of the under-18 population. The percentage is defined as the ratio of under-18 residents to total population, as reported by the Census Bureau.
Who It Affects
Federal cancer research funding programs (notably those funds managed by agencies like NIH/NCI) and the institutions that receive their grants, alongside Census data producers. Pediatric patients and families stand to be directly affected by how funds are allocated.
Why It Matters
It creates a population-based baseline for pediatric cancer research funding, anchoring allocations to demographic data and encouraging a steady stream of resources for childhood cancers while linking budgeting to census reporting.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act seeks to ensure that pediatric cancer research receives a measurable and predictable portion of federal cancer research funding. Beginning in fiscal year 2026, and in every year thereafter, the total federal funds obligated for cancer research must be allocated so that the share directed to pediatric cancer research matches a Census-derived percentage.
This percentage is calculated as the share of the U.S. population under 18, measured at the end of the preceding fiscal year using data from the Bureau of the Census. Put simply, the size of the pediatric cancer research slice should reflect how large the country’s under-18 population is relative to the overall population, and this rule applies to all federal cancer research obligations.
The bill specifies the President’s responsibility to ensure compliance but does not lay out penalties or private rights of action. In effect, the act ties funding decisions to census demographics, potentially shifting resources across pediatric and non-pediatric cancer research as the population metrics change over time.
The Five Things You Need to Know
The share of federal cancer research funds dedicated to pediatric cancer must equal the Census-based share of the under-18 population.
The percentage is calculated as the ratio of under-18 residents to total residents, according to the Census Bureau, as of the end of the preceding fiscal year.
The rule takes effect in FY2026 and applies in every subsequent fiscal year.
The calculation applies to all federal funds obligated for cancer research (not limited to a single agency).
The bill assigns a presidential budgeting obligation to meet this share, without specifying enforcement mechanisms beyond executive compliance.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This section provides the official short title of the act, the Fairness to Kids with Cancer Act of 2025, for citation purposes. It establishes the naming convention to be used in all references to the statute.
Percentage of federal cancer research funds for pediatric cancer research
Section 2 sets the core funding rule. Subsection (a) provides that for fiscal year 2026 and each following year, the President must ensure that the percentage of total federal funds obligated for cancer research that is dedicated to pediatric cancer research equals the percentage described in subsection (b). Subsection (b) defines that percentage as the ratio of the number of individuals under 18 residing in the United States at the end of the preceding fiscal year to the total number of individuals residing in the United States at that time, with the calculation performed as determined by the Bureau of the Census. This creates a moving, population-based target for pediatric cancer research funding across the federal research portfolio.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Pediatric cancer patients and their families, who would see a dedicated share of federal research funding directed toward pediatric cancer-related studies and potential improvements in treatment options.
- The National Institutes of Health (especially the National Cancer Institute) and other federal cancer research agencies, which would adjust annual grant allocations to align with the Census-based share for pediatric cancer research.
- Universities, research hospitals, and pediatric oncology centers that rely on federal grants for pediatric cancer programs and clinical trials.
- Pediatric oncology researchers and clinical trial networks that benefit from a steadier, population-aligned funding stream.
- Pediatric cancer advocacy organizations that track funding and advocate for resources aligned with demographic measures.
Who Bears the Cost
- Non-pediatric cancer research programs and adult-onset cancer research may experience relative shifts in funding as pediatric share increases or decreases.
- Grant offices and budget planners at federal agencies will face the administrative task of recalibrating allocations annually to match the Census-based share.
- Some research institutions with broad cancer portfolios may experience portfolio realignments to meet the proportional share.
- Overall federal budgeting could see more volatility in pediatric cancer funding year to year due to population fluctuations captured by Census data.
Key Issues
The Core Tension
The central tension is between allocating funds based on population share (a democratic principle of proportionality) and aligning research funding with disease burden, urgency, and potential for impact in pediatric cancer. The Census-based approach solves some fairness questions but may misalign with clinical need or long-term research planning, creating a trade-off between equity and strategic funding efficiency.
The bill ties the pediatric cancer funding share to a demographic metric, which introduces a direct link between population counts and research budgeting. While this can improve transparency and equity, it also creates potential disparities between disease burden, incidence, and mortality across cancers and age groups.
The requirement relies on Census data reported annually, which can change with population estimates and migration patterns, potentially prompting regular shifts in funding allocations. The bill, as written, does not specify penalties for noncompliance or a private right of action, nor does it outline a transition path for agencies to implement the new budgeting rule mid-fiscal year.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.